Xcout Intel
Elypta competitors & alternatives
The 12 closest competitors and alternatives to Elypta among diagnostics companies — ranked by similarity to what Elypta actually does, not by market-cap band.
Subscribe to see Elypta’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Elypta
Elypta AB is a private biotech company headquartered in Solna, Sweden, operating on the Karolinska Institute campus. The firm focuses on developing cancer detection tests based on metabolism and liquid biopsy biomarkers.
Elypta at a glance
Elypta is a diagnostics company headquartered in Sweden. It has raised at least $27.8M across the 2 funding rounds on record. Its most recent funding round, Seed, raised $21M in June 2022. Xcout tracks 12 named people at Elypta, including Karl Bergman (CEO).
Elypta leadership
- Karl BergmanCEO
- Johan VikströmChief Financial Officer
- Volker LiebenbergChief Medical Officer
- Francesco Gattoco-founder and CSO
- Dilruba AhmedVP of Quality & Regulatory Affairs
- Gabriel OrtizVP of Software Engineering
6 more named people on record for Elypta, with roles, board committees and tenure — see the full roster →
Elypta funding rounds
At least $27.8M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $21M | 9 named | |
| — | $6.8M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Elypta competitors
Ranked by semantic similarity — how close each company is to Elypta by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Predicta Biosciences is a precision oncology company that builds a molecular insights platform for blood cancer care. By utilizing a single blood sample, the company integrates multiomics and liquid biopsies to generate longitudinal genomic and immune insights for diagnostics.
Medical Diagnostics, Biomedical Engineering, Liquid Biopsy
Nucleix is a liquid biopsy company headquartered in Rehovot, Israel. It aims to revolutionize cancer treatment through earlier disease detection, focusing on interventions that can bring the greatest impact.
Biotechnology / Diagnostics
Devyser develops and provides diagnostic DNA test kits and integrated software for clinical laboratories. The company's products support various medical fields, including post-transplantation monitoring, oncology, hereditary cancer, reproductive health, and cardiovascular diseases.
Diagnostics/Tools
Adela, Inc. is an epigenomics-focused biotechnology company headquartered in Foster City, California. The company is advancing breakthrough approaches for the early detection of multiple types of cancer through blood tests.
Biotechnology
Mercy BioAnalytics, Inc. is a privately held biotechnology company founded in 2018 and headquartered in Waltham, Massachusetts. The company is dedicated to developing early diagnostics and detection technologies.
Biotechnology
SAGA Diagnostics provides ultra-sensitive, blood-based molecular residual disease (MRD) detection and monitoring tests for cancer patients. The company's flagship platform, Pathlight, uses tumor whole-genome sequencing and personalized digital PCR assays to detect circulating tumor DNA, primarily serving clinicians and biopharmaceutical partners for early cancer detection and treatment tracking.
Biotechnology
Resolution Bioscience is a precision medicine company specializing in cancer diagnostics, DNA sequencing, and liquid biopsy, located in Bellevue, Washington.
Biotech
Precede Biosciences is a biotechnology company developing blood-based liquid-biopsy technologies for molecular profiling of cancer. Its tests are intended to support oncology research, precision treatment decisions, and pharmaceutical drug-development programs.
Biotech
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
Biotechnology
Predicine Holdings Ltd provides next-generation liquid biopsy platforms and molecular profiling services for cancer research and precision medicine. The company utilizes proprietary blood- and urine-based assays to analyze circulating tumor DNA and RNA, serving biopharmaceutical partners and clinical researchers in oncology drug development and clinical trials.
Similar diagnostics company
Naveris, Inc. is a biotechnology research and cancer detection company located in Waltham, Massachusetts. It specializes in developing advanced molecular diagnostic blood tests for HPV-associated cancers.
Biotechnology
Capio Biosciences is an oncology diagnostics company that develops advanced technologies for capturing and analyzing circulating tumor cells (CTCs) from whole blood. Its proprietary CapioCyte platform offers enhanced sensitivity compared to traditional methods, serving as a research tool designed to help oncologists make informed cancer treatment decisions.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Elypta and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Elyptaand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →